Back

IFN-γ Orchestrates Coordinated Immunosuppression in Head and Neck Squamous Cell Carcinoma Through JAK-STAT-IRF8 Signaling: A Transcriptome-Wide Computational Analysis

Abdelhamid, A.; Saad, e.

2026-03-29 genetics
10.64898/2026.03.26.714228 bioRxiv
Show abstract

BackgroundInterferon-gamma (IFN-{gamma}) is the primary effector cytokine of adaptive anti-tumor immunity, yet it paradoxically induces a potent immunosuppressive tumor microenvironment (TME). The full mechanistic scope of this paradox in head and neck squamous cell carcinoma (HNSC) has not been characterized at the transcriptomic scale. MethodsUsing TCGA HNSC RNA-seq data (n = 522), we applied an integrated computational pipeline: Spearman correlation analysis, principal component analysis (PCA), UMAP, K-means clustering (k = 4), Random Forest regression, deep neural networks, permutation importance, JAK-STAT cascade mapping, and DNN-based transcriptome-wide mediation analysis across 57 IFN-{gamma} pathway and 78 immunosuppressive genes. ResultsIFN-{gamma} pathway activity was universally and positively correlated with six immunosuppressive axes, including checkpoints (CD274; LAG3; IDO1), Tregs, myeloid suppression, and tryptophan catabolism. K-means clustering identified four immunologically distinct tumor subgroups. DNN models predicted suppressive TME. Permutation importance identified IRF8 as the dominant mediator linking IFN-{gamma} signaling to immunosuppression. DNN mediation analysis identified PDCD1LG2 (PD-L2) as the strongest intermediary between IFNG and PD-L1 regulation, followed by JAK2 and GBP5. ConclusionsIFN-{gamma} orchestrates coordinated immunosuppression in HNSC through JAK-STAT-IRF8 signaling. PDCD1LG2 and JAK2 are actionable mediators of this paradox, supporting combination strategies co-targeting IFN-{gamma}-induced checkpoint induction and direct checkpoint blockade in HNSC immunotherapy. GRAPHICAL ABSTRACT

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Frontiers in Immunology
586 papers in training set
Top 0.2%
15.4%
2
Scientific Reports
3102 papers in training set
Top 5%
10.6%
3
PLOS ONE
4510 papers in training set
Top 30%
5.1%
4
Cancers
200 papers in training set
Top 1%
4.5%
5
BMC Cancer
52 papers in training set
Top 0.5%
3.8%
6
eBioMedicine
130 papers in training set
Top 0.5%
2.9%
7
Frontiers in Genetics
197 papers in training set
Top 3%
2.7%
8
iScience
1063 papers in training set
Top 11%
2.0%
9
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.6%
1.8%
10
PLOS Computational Biology
1633 papers in training set
Top 15%
1.8%
50% of probability mass above
11
Archives of Clinical and Biomedical Research
28 papers in training set
Top 0.6%
1.8%
12
OncoImmunology
22 papers in training set
Top 0.2%
1.8%
13
PeerJ
261 papers in training set
Top 7%
1.7%
14
BMC Bioinformatics
383 papers in training set
Top 4%
1.7%
15
Cell Death Discovery
51 papers in training set
Top 0.6%
1.6%
16
The Journal of Pathology
22 papers in training set
Top 0.2%
1.4%
17
International Immunopharmacology
15 papers in training set
Top 0.2%
1.3%
18
Molecular Oncology
50 papers in training set
Top 0.5%
1.3%
19
Cell Communication and Signaling
35 papers in training set
Top 0.7%
1.2%
20
Biomedicines
66 papers in training set
Top 2%
1.0%
21
eLife
5422 papers in training set
Top 52%
0.9%
22
Computers in Biology and Medicine
120 papers in training set
Top 4%
0.8%
23
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.2%
0.8%
24
Viruses
318 papers in training set
Top 5%
0.8%
25
BMC Medicine
163 papers in training set
Top 6%
0.8%
26
Frontiers in Bioinformatics
45 papers in training set
Top 0.8%
0.8%
27
Biomedicine & Pharmacotherapy
43 papers in training set
Top 1.0%
0.8%
28
Cell & Bioscience
14 papers in training set
Top 0.1%
0.8%
29
Communications Biology
886 papers in training set
Top 23%
0.8%
30
Virus Research
36 papers in training set
Top 1%
0.8%